Safety and Utility of Transjugular Liver Biopsy in Hematopoietic Stem Cell Transplant Recipients
|
|
- Joanna Oliver
- 6 years ago
- Views:
Transcription
1 CLINICAL STUDY Safety and Utility of Transjugular Liver Biopsy in Hematopoietic Stem Cell Transplant Recipients Bela Kis, MD, PhD, Vishwan Pamarthi, MD, Chieh-Min Fan, MD, Dmitry Rabkin, MD, PhD, and Richard A. Baum, MD ABSTRACT Purpose: Hematopoietic stem cell transplant (HSCT) recipients are at high risk in the setting of percutaneous liver biopsy as a result of comorbid coagulopathy and ascites, and are commonly referred to undergo transjugular liver biopsy. The present study was performed to assess the safety and utility of transjugular liver biopsy in HSCT recipients and to analyze the correlation between corrected hepatic sinusoidal pressure gradient (CHSPG) and pathologic diagnoses. Materials and Methods: Data from reports of transjugular liver biopsy procedures, pathology reports, and laboratory values of 141 consecutive HSCT recipients who underwent transjugular liver biopsy with pressure measurement between January 2005 and August 2011 in a single institution were retrospectively reviewed and analyzed. Results: A total of 166 biopsy procedures were performed in 141 patients. Technical success rate was 98.8%. Biopsy was diagnostic in 95.7% of patients. There were three major complications (1.8%), including one death. CHSPG in patients with venoocclusive disease (VOD) was significantly higher (Po.001) than in those without VOD (16.2 mm Hg 9.2 vs 5.6 mm Hg 3.7). A CHSPG of 10 mm Hg or higher was 90.8% specific and 77.3% sensitive for VOD. Conclusions: The present data show that transjugular liver biopsy is a relatively safe procedure that provides important information for the clinical management of patients with HSCT. Measurement of CHSPG during the procedure can support the diagnosis of VOD. ABBREVIATIONS ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CHSPG = corrected hepatic sinusoidal pressure gradient, GVHD = graft-versus-host disease, HSCT = hematopoietic stem cell transplantation, INR = International Normalized Ratio, PT = prothrombin time, VOD = venoocclusive disease Hematopoietic stem cell transplantation (HSCT) therapy is primarily used to treat hematologic malignant disorders, but its indication is expanding with the development of novel techniques that have led to improved outcomes. Worldwide, 50,417 HSCT procedures were performed in 2006 (1), and the number of patients receiving transplants From the Department of Radiology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St., Boston, MA Received June 2, 2012; final revision received September 10, 2012; accepted September 13, Address correspondence to B.K.; kisbela@hotmail.com From the SIR 2012 Annual Meeting. B.K. was supported by the 2011/12 Radiological Society of North America Research Fellow Grant. Statistical consultation was received from a Harvard Catalyst biostatistician. None of the authors have identified a conflict of interest. & SIR, 2013 J Vasc Interv Radiol 2013; 24: from unrelated donors is expected to double in the next 5 years (2). Graft-versus-host disease (GVHD) of the liver and hepatic venoocclusive disease (VOD) are unique complications of HSCT and are among the leading causes of morbidity and mortality in HSCT recipients. The morbidity rate related to hepatic involvement can be as high as 80% and is responsible for 4% 14% of deaths (3). The treatment of this high-morbidity patient population is complicated by the uncertainty of the diagnosis based on the clinical, laboratory, and imaging findings (4). Therefore, liver biopsy is often performed as part of diagnostic workup. A liver biopsy specimen can be obtained with a percutaneous or transjugular approach. However, many patients with HSCT are at risk for bleeding secondary to thrombocytopenia and/or coagulopathy, and many have ascites, which is a relative contraindication to percutaneous biopsy. Consequently, patients with HSCT are often referred for transjugular liver biopsy. An additional benefit of transjugular liver biopsy is the ability to measure the corrected hepatic sinusoidal pressure gradient (CHSPG) during the procedure.
2 86 Safety/Utility of Transjugular Liver Biopsy in HSC Transplants Kis et al JVIR Despite these advantages, transjugular liver biopsy in HSCT recipients is regarded as a high-risk procedure based on small-scale published studies that reported very high complication rates for transjugular liver biopsy in HSCT recipients (5 7). Oshrine et al (5) reported an 80% major complication rate (four of five patients) of transjugular liver biopsy in pediatric HSCT recipients. Shulman et al (6) and Chahal et al (7) reported 31% (nine of 29 patients) and 11% (three of 27 patients) major complication rates, respectively, in adult HSCT recipients. However, as the number of patients undergoing HSCT increases (2), requests for transjugular liver biopsy are expected to increase as well (8). There is a need in the scientific literature to better evaluate the risks of transjugular liver biopsy in HSCT recipients. The purposes of the present study were to assess the safety and utility of transjugular liver biopsy in a larger patient population to estimate the potential risks and benefits of the procedure and to analyze the correlation between CHSPG and the pathologic diagnosis obtained through biopsy. MATERIALS AND METHODS This study was approved by the institutional review board of our hospital. Medical records of consecutive patients who underwent transjugular liver biopsy with venous pressure measurements between January 2005 and August 2011 in our hospital were retrospectively reviewed and analyzed. This included a total of 166 transjugular liver biopsy procedures performed in 141 HSCT recipients. The HSCT recipients who underwent transjugular liver biopsy included 87 men and 54 women with a mean age of 45.3 years 13.2 (standard deviation). Twenty-two patients underwent more than one biopsy procedure; 19 patients underwent two procedures each and three patients underwent three each. One to 10 biopsy samples were obtained per patient (mean, among 164 patients; there was one failed biopsy and one procedure for which the number of samples was not reported). The biopsies were performed by a single team of interventional radiologists in a digital fluoroscopy suite by using the following technique. The right internal jugular vein was accessed under sonographic guidance and a 10- F 40-cm vascular sheath was advanced into the inferior vena cava. Hepatic venography was performed through a 5-F multipurpose angled catheter to determine anatomy and patency of the selected hepatic vein and the optimal positioning for biopsy. The multipurpose angled catheter was exchanged for an 11.5-mm occlusion balloon catheter, and wedged and free hepatic venous pressures were measured (9,10). The CHSPG was calculated by subtracting free hepatic venous pressure from wedged hepatic venous pressure. The balloon catheter was exchanged for a 14- gauge transjugular guiding cannula from a Liver Access and Biopsy set (Cook, Bloomington, Indiana), which was positioned in the selected hepatic vein. A 19-gauge core biopsy needle was then delivered through the cannula into the right hepatic lobe, and biopsy specimens were obtained under fluoroscopic guidance. Biopsy samples were immediately placed in formalin and sent for histologic analysis. Samples were also sent in saline solution for microbiology cultures if requested by the clinical team. The number of samples obtained was at the discretion of the interventional radiologist and depended on the number of studies ordered by the clinical team and on the size of the obtained tissue samples. All data presented in the present study were collected from retrospective review of patients computerized medical records. The records included charts, reports of the transjugular liver biopsy procedures, pathology reports of the biopsy specimens, and laboratory values. The analyzed laboratory values were hematocrit level, platelet count, International Normalized Ratio (INR), prothrombin time (PT), aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, alkaline phosphatase (ALP) level, total bilirubin level, creatinine level, and blood urea nitrogen (BUN) level. Complications were defined as adverse events that occurred as a direct result of the liver biopsy. These were further classified into minor and major complications according to the Society of Interventional Radiology classification system (11). The need for transfusion of red blood cells within 24 hours after biopsy was considered a major complication. In general, platelet counts of more than 50/mL and INR values lower than 2 were preferred in patients who underwent transjugular liver biopsy. However, the interpretation of these guidelines varied on a case-by-case basis. Platelet transfusions were administered to 57 patients before the procedure, in whom the pretransfusion platelet count was 24,900/mL 12,700 and increased to 69,400/mL 22,700. The final preprocedural platelet count among all patients was 114,800/mL 89,000 (n ¼ 165; one patient had no data available). The preprocedural INR was (n ¼ 159; seven patients had no data available) and PT was 37.0 seconds 13.7 (n ¼ 150; 16 patients had no data available). None of the HSCT recipients in the study had an INR greater than 2, and none received fresh frozen plasma transfusion before the procedure. The 24-hour postprocedural hematocrit level of 30.6% 5.2 (n ¼ 149; 17 patients had no data available) was not significantly different compared with the preprocedural value of 31.3% 5.5 (N ¼ 166). The patients had elevated liver function test results (ALT, U/L 737.7; AST, U/L 1,011.4; ALP, U/L 338.5; total bilirubin, 7.8 mg/dl 9.4; all measurements recorded in all 166 patients). Preprocedural creatinine and BUN measurements were 1.1 mg/dl 1.0 and 33.9 mg/dl 28.2, respectively (N ¼ 166). Statistical analysis was performed with SigmaStat (version 2.03) statistical software (SPSS, Chicago, Illinois). Data are presented as means standard deviation. A P value lower than.05 was considered to be statistically significant. When data in two groups passed the normality and equal variance tests, differences between the two
3 Volume 24 Number 1 January groups were assessed by Student t test. When a Student t test could not be performed, the two groups were compared with a Mann Whitneyrank-sum test. When data in multiple groups passed the normality and equal variance tests, differences between multiple groups were assessed by one-way analysis of variance followed by Tukey comparison tests. When one-way analysis of variance could not be performed, groups were compared with Kruskal Wallis one-way analysis of variance on ranks, followed by Dunn pairwise multiple comparison procedures. To study the relationship of the histopathologic diagnosis of VOD to the range of CHSPG values, a series of 2 2 contingency tables was constructed by using a Fisher exact test. For each of the pressure gradient values, the sensitivity, specificity, and positive and negative predictive values for finding VOD were calculated. Logistic regression analysis curves of specificity and sensitivity of CHSPG for VOD were constructed by MedCalc (version ) statistical software (MedCalc, Mariakerke, Belgium). Figure 1. CHSPG in HSCT recipients with different histopathologic diagnoses. Others indicates patients with a histopathologic diagnosis other than GVHD or VOD (*P o.05). RESULTS During the study period, 166 transjugular liver biopsy procedures were performed in 141 patients who underwent HSCT. The technical success was 98.8% (164 of 166; one sample had insufficient tissue for diagnosis and one biopsy failed as a result of patient agitation, although pressure measurements were performed). There were three major complications (1.8%): one patient developed arteriobiliary fistula, which required embolization; one patient required blood transfusion within 24 hours after the procedure as a result of decreasing hematocrit level; and one patient experienced subcapsular and intraperitoneal hemorrhage leading to death within 36 hours. The overall mortality rate was 0.6%. Histologic analysis of the biopsy samples led to a diagnosis in 95.7% of cases (158 of 165; there was one nondiagnostic sample and six samples with nonspecific findings per pathology report). The histologic diagnosis was GVHD in 88 patients, VOD in 31 patients, coexistence of VOD with GVHD in 13 patients, other pathologic process (eg, lymphoma, steatohepatitis, drug toxicity, extramedullary hematopoiesis) in 27 patients, and nonspecific in six patients. Based on the histopathologic diagnosis, the patients were divided into four groups for further analysis of CHSPG data and laboratory values: patients with GVHD, patients with VOD, patients with coexistence of VOD with GVHD, and patients with another histologic diagnosis. The final group included patients with nonspecific histologic findings. The CHSPG was significantly higher (P o.001) in the VOD and VOD/GVHD groups compared with the other groups (Fig 1). When patients were divided into two groups patients with VOD (n ¼ 44) and patients without VOD (n ¼ 121), the mean CHSPG in the VOD group ( ) was significantly higher (P o.001) than in the non-vod group ( ). Figure 2. Sensitivity and specificity curves of CHSPG for VOD. The solid and dashed thick lines represent sensitivity and specificity, respectively. The thin lines paralleling the respective thick lines represent 95% confidence intervals. Logistic regression analysis curves of specificity and sensitivity of CHSPG for VOD are shown in Figure 2. Figure 2 demonstrates that a CHSPG of 10 mm Hg or higher provides 90.8% specificity and 77.3% sensitivity for the diagnosis of VOD. Specificity, sensitivity, and positive/ negative predictive values for the 9 11 mm Hg range of CHSPG are shown in Table 1. Comparison of the laboratory values of the GVHD and VOD groups are shown in Table 2. Patients with VOD had significantly higher INR, PT, AST, creatinine, and BUN values, whereas patients with GVHD had significantly higher ALP levels. There was no statistically significant difference in total bilirubin and ALT levels between the two groups.
4 88 Safety/Utility of Transjugular Liver Biopsy in HSC Transplants Kis et al JVIR DISCUSSION The number of patients receiving allogenic HSCT is increasing worldwide, and hepatic complications occur in a significant proportion of HSCT recipients (1,2). Despite human leukocyte antigen identity between a patient and donor, approximately 40% of recipients of human leukocyte antigen identical grafts develop GVHD, and the liver is involved in 50% of these cases (2). Histologically, hepatic GVHD presents as lymphocytic infiltration of the portal areas, pericholangitis, endothelial injury, and bile duct destruction (12). VOD is characterized clinically by the triad of hepatomegaly, ascites/weight gain, and jaundice (13). VOD develops secondary to high-dose cytoreductive therapy in susceptible patients, resulting in endothelial injury in sinusoids and small hepatic venules with consequent activation of the coagulation cascade. This leads to clot formation and obliteration of the hepatic venules (13). The clinical manifestations of liver diseases caused by GVHD or VOD can mimic other hepatic complications of HSCT, such as viral hepatitis (herpes simplex virus, adenovirus, varicella virus, hepatitis B and C viruses), fungal infection, leukemic infiltration, drug toxicity, and cholestasis secondary to septicemia, total parenteral nutrition, or medications (4,6). GVHD and VOD require specific treatment, and early treatment improves the probability of treatment success (2,8,13). Therefore, timely and accurate diagnosis is essential. When the diagnosis is unclear based on the clinical picture, liver biopsy is required. Even with Table 1. Specificity, Sensitivity, and Positive and Negative Predictive Values for Venoocclusive Disease based on CHSPG CHSPG (%) Statistic 4 8mmHg 4 9mmHg 4 10 mm Hg Sensitivity Specificity PPV NPV CHSPG ¼ corrected hepatic sinusoidal pressure gradient, NPV ¼ negative predictive values, PPV ¼ positive predictive values. a typical clinical presentation, biopsy may be necessary. According to the study of Esposito et al (14), 66% (14 of 21) of HSCT recipients had a different pathologic diagnosis than what was clinically suspected. Shulman et al (6) reported that liver histologic findings provided additional information that was beneficial for HSCT recipient management in 88% of cases (53 of 60 patients). Most of the time, HSCT recipients are referred for transjugular liver biopsy as a result of thrombocytopenia and/or coagulopathy. In addition, ascites commonly presents in HSCT recipients, which may defer percutaneous biopsy. Previous small-scale studies (5 7) of transjugular liver biopsy in HSCT recipients (the largest included 29 patients) reported major complication rates as low as 11% and as high as 80%. Our present retrospective analysis of 166 transjugular liver biopsies in 141 HSCT recipients revealed a 1.8% major complication rate and a 0.6% mortality rate. Reported complication rates of transjugular liver biopsies involving more than 100 patients range between 2.4% and 6% (15 17). In the present study, the technical success rate of transjugular liver biopsy in HSCT recipients was 98.8%. Biopsy samples led to histologic diagnosis in 95.7% of cases, which highlights the clinical utility of the procedure. Our results are comparable to transjugular liver biopsy data in the general patient population, which were reported to show a technical success rate of 96.8% and a histologic diagnosis rate of 96.1% in a metaanalysis of 64 series reporting 7,649 transjugular liver biopsies (18). The most frequent histologic diagnosis in our HSCT patient population was GVHD, followed by VOD, and this corresponds to data described in the literature (7). The distinction between GVHD and VOD is very important because GVHD requires high-dose immunosuppressive therapy (2), whereas the treatment of VOD primarily includes supportive care, fibrinolysis, and anticoagulation (13). The measurement of CHSPG has been reported in small series to discriminate between VOD and other liver pathologic processes in HSCT recipients (6). Our data in a relatively large patient population demonstrate again that measurement of CHSPG during the transjugular liver biopsy procedure can support the diagnosis of VOD. Table 2. Laboratory Values of Patients with GVHD and VOD Parameter GVHD VOD P Value Normal Range INR o PT, s o ALT, U/L AST, U/L o ALP, U/L o Total bilirubin, mg/dl Creatinine, mg/dl o BUN, mg/dl o Values presented as mean standard deviation. ALP ¼ alkaline phosphatase, ALT ¼ alanine aminotransferase, AST ¼ aspartate aminotransferase, BUN ¼ blood urea nitrogen, GVHD ¼ graft-versus-host disease, INR ¼ International Normalized Ratio, PT ¼ prothrombin time, VOD ¼ venoocclusive disease.
5 Volume 24 Number 1 January A CHSPG of 10 mm Hg or higher is 90.8% specific and 77.3% sensitive for VOD. Therefore, measurement of CHSPG can lead to initiation of specific treatment days before the final histologic diagnosis and potentially reduce morbidity and mortality in HSCT recipients. In addition, according to published data, CHSPG may be helpful in determining the prognosis of patients with VOD (6). Analysis of laboratory values for HSCT recipients who underwent transjugular liver biopsy at our institution showed that the patients had abnormal liver function test results, as expected. The average red blood cell count and platelet count were lower than normal range, and the INR and PT values were slightly increased. These results are not surprising in this patient population. There were a few interesting findings when the laboratory values of patients with GVHD were compared with those of patients with VOD. Patients with GVHD had significantly higher ALP levels. This finding corresponds to liver histologic findings in GVHD, which show lymphocytic infiltration of portal areas, pericholangitis, and bile duct destruction. In the liver, ALP is found in the epithelial cells lining the biliary tract (19), and it is well known that plasma ALP level is increased in pathologic conditions involving the biliary tree (20). Another interesting finding was the significantly increased creatinine and BUN levels in patients with VOD compared with those with GVHD. Increased risks of acute renal failure have been observed in patients with VOD, whereas GVHD was not associated with renal impairment (21). The relationship between VOD and renal impairment is not clear; decreased hepatic clearance of nephrotoxic endotoxins absorbed from the gut may play a role (22). The main deficiency of the present study is its retrospective nature. In addition, we report a single institution s experience, and patient selection was at the preference of the stem cell transplant clinical team, which may have skewed our results. Despite these limitations, the value of our investigation lies in the size of our patient population, which, to our knowledge, is nearly five times the size of the next largest series. In summary, the present study supports the relative safety of transjugular liver biopsy in HSCT recipients. The measurement of CHSPG during the transjugular liver biopsy procedure can provide important diagnostic information days before the availability of the pathologic diagnosis, and may accelerate the initiation of diseasespecific therapy. This additional information makes transjugular liver biopsy the preferred route even in patients who otherwise would be eligible for percutaneous biopsy, particularly when VOD is a consideration in the differential diagnosis. REFERENCES 1. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: Locasciulli A, Alberti A, de Bock R, et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group Infectious Diseases Working Party. Bone Marrow Transplant 1994; 14: Carreras E, Granena A, Navasa M, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66: Oshrine B, Lehmann LE, Duncan CN. Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2011; 33:e92 e Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: Chahal P, Levy C, Litzow MR, Lindor KD. Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol 2008; 23: Mahgerefteh SY, Sosna J, Bogot N, Shapira MY, Pappo O, Bloom AI. Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. Radiology 2011; 258: Smith TP, Kim CY, Smith AD, Janas G, et al. Hepatic venous pressure measurements: comparison of end-hole and balloon catheter methods. J Vasc Interv Radiol 2012; 23: Maleux G, Willems E, Fieuws S, et al. Prospective study comparing different indirect methods to measure portal pressure portal pressure. J Vasc Interv Radiol 2011; 22: Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003; 14(suppl):S199 S Fujii N, Takenaka K, Shinagawa K, et al. Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27: Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs AK. Venoocclusive disease: update on clinical management. World J Gastroenterol 2007; 13: Esposito AA, Nicolini A, Meregaglia D, Sangiovanni A, Biondetti P. Role of transjugular liver biopsy in the diagnostic and therapeutic management of patients with severe liver disease. Radiol Med 2008; 113: Bull HJ, Gilmore IT, Bradley RD, Marigold JH, Thompson RP. Experience with transjugular liver biopsy. Gut 1983; 24: Choh J, Dolmatch B, Safadi R, et al. Transjugular core liver biopsy with a 19-gauge spring-loaded cutting needle. Cardiovasc Intervent Radiol 1998; 21: Smith TP, Presson TL, Heneghan MA, Ryan JM. Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. AJR Am J Roentgenol 2003; 180: Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy indications, adequacy, quality of specimens, and complications a systematic review. J Hepatol 2007; 47: Jacoby F, Martin BF. The relationship of bile alkaline phosphatase to histochemically detectable alkaline phosphatase in the biliary tract; including reference to the histology of the gall-bladder epithelium. J Anat 1951; 85: Popper H, Schaffner F. Pathophysiology of cholestasis. Hum Pathol 1970; 1: Hingorani SR, Guthrie K, Batchelder A, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005; 67: McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:
Lymphoma and Hematological Conditions: I. Lymphoma and Liver Complications of Bone Marrow Transplant
REVIEW Lymphoma and Hematological Conditions: I. Lymphoma and Liver Complications of Bone Marrow Transplant Oliver Tavabie, M.R.C.P., and Abid R. Suddle, M.D. Liver abnormalities are frequently seen in
More informationTransjugular Liver Biopsy in Patients with Hematologic Malignancy and Severe Thrombocytopenia
Transjugular Liver Biopsy in with Hematologic Malignancy and Severe Thrombocytopenia Michael J. Wallace,MD,Aida Narvios,MD,Benjamin Lichtiger,MD,Kamran Ahrar,MD, Frank A. Morello,Jr,MD,Sanjay Gupta,MD,David
More informationNon-infectious hepatic complications in patients with GVHD
Non-infectious hepatic complications in patients with GVHD Tapani Ruutu Helsinki University Central Hospital Liver dysfunction in allogeneic stem cell transplantation injury secondary to the cytoreductive
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationAspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis
The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (2013) 661e675 Brief Articles Improved Survival over the Last Decade in Pediatric Patients Requiring Dialysis after Hematopoietic Cell Transplantation American Society for
More informationTransjugular Intrahepatic
Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Clinical and Procedural Review Mark R. Werley, M.D. and John Briguglio, M.D. Lancaster Radiology Associates, Ltd. INTRODUCTION This article reviews
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationPercutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden
Original Article Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden Eun L. Langman 1, Paul V. Suhocki 1, Herbert I. Hurwitz 2, Michael A. Morse
More informationTransjugular Intrahepatic Portosystemic Shunt Reduction for Management of Recurrent Hepatic Encephalopathy
CLINICAL IMAGES Ochsner Journal 17:311 316, 2017 Ó Academic Division of Ochsner Clinic Foundation Transjugular Intrahepatic Portosystemic Shunt Reduction for Management of Recurrent Hepatic Encephalopathy
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationIntraarterial catheter guided steroid administration in treatment of steroid refractory gastrointestinal GVHD after HSCT
Intraarterial catheter guided steroid administration in treatment of steroid refractory gastrointestinal GVHD after HSCT Poster No.: C-1041 Congress: ECR 2013 Type: Authors: Keywords: DOI: Scientific Exhibit
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationNothing to disclose. Title of the presentation - Author
Nothing to disclose Title of the presentation - Author 1 www.ebmt.org Complications after HSCT Alicia Rovó MD London 9/04/2013 Introduction Risk factors for transplant complication Type of complications
More informationHOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO
HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO The identification of abnormal liver enzymes usually indicates liver damage but rarely
More informationUnderstanding Blood Tests
PATIENT EDUCATION patienteducation.osumc.edu Your heart pumps the blood in your body through a system of blood vessels. Blood delivers oxygen and nutrients to all parts of the body. It also carries away
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationAbstract 815. Richardson P, Carreras E, Pagliuca A, Ryan R, Tappe W, and Mohty M
A Pooled Analysis of Survival by Defibrotide Timing of Initiation in Adults with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Following Hematopoietic Stem Cell Transplant (HSCT) Abstract
More informationPathophysiology I Liver and Biliary Disease
Pathophysiology I Liver and Biliary Disease The Liver The liver is located in the right upper portion of the abdominal cavity just beneath the right side of the rib cage. The liver has many functions that
More information1/10/2019. General clinical features. Possible risk factors. Risk factors
HSOS Seth Eisenberg RN OCN BMTCN Professional Practice Coordinator, Infusion Services Seattle Cancer Care Alliance Revised 1/2018 General clinical features Weight gain: R/T fluid retention Hepatomegaly:
More informationHyperbilirubinemia and Gallbladder Complications in Pediatric Hematopoietic Stem Cell Transplant Patients
Hyperbilirubinemia and Gallbladder Complications in Pediatric Hematopoietic Stem Cell Transplant Patients Item Type Thesis Authors Makinde, Ambimbolu S. Rights Copyright is held by the author. Digital
More informationGeneral clinical features
HSOS Seth Eisenberg RN OCN BMTCN Professional Practice Coordinator, Infusion Services Seattle Cancer Care Alliance Revised 1/2018 General clinical features Weight gain: R/T fluid retention Hepatomegaly:
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationEVALUATION & LISTING. Your Child s Liver Transplant Evaluation. What is the Liver?
EVALUATION & LISTING Your Child s Liver Transplant Evaluation The University of Michigan is a national leader in liver transplantation, as well as the surgical and medical management of patients with liver
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationRoutine Clinic Lab Studies
Routine Lab Studies Routine Clinic Lab Studies With all lab studies, a Tacrolimus level will be obtained. These drug levels are routinely assessed to ensure that there is enough or not too much anti-rejection
More informationInfective hepatic complications in HSCT patients. Simone Cesaro. Pediatric Hematology Oncology Verona, Italy. Session II: organ specific complications
Session II: organ specific complications Infective hepatic complications in HSCT patients Simone Cesaro Pediatric Hematology Oncology Verona, Italy simone.cesaro@ospedaleuniverona.it Liver complications
More informationAMR in Liver Transplantation: Incidence
AMR in Liver Transplantation: Incidence Primary AMR 1/3 to 1/2 of ABO-incompatible transplants Uncommon with ABO-compatible transplant Secondary AMR Unknown incidence: rarely tested Why is AMR uncommon
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationNYU School of Medicine Department of Radiology Rotation-Specific House Staff Evaluation
Vascular & Interventional Radiology Rotation 1 Core competency in vascular and interventional radiology during the first resident rotation consists of clinical objectives, technical objectives and image
More informationLiver Disease. By: Michael Martins
Liver Disease By: Michael Martins Recently I have been getting a flurry of patients that have some serious liver complications. This week s literature review will be the dental management of the patients
More informationAn Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD
Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different
More informationDepartment of Clinical Haematology Oxford BMT Programme Management of Hepatic Veno-occlusive Disease (VOD)
Management of Hepatic Veno-occlusive Disease (VOD) Definition Hepatic veno-occlusive disease (VOD) or sinusoidal obstructive syndrome (SOS) is a disorder characterised by obstruction of small intra-hepatic
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
More informationAnatomy Jessica Ferguson Ashley Dobos May 31, 2006 LIVER
Anatomy Jessica Ferguson Ashley Dobos May 31, 2006 LIVER 1) Other Names: Reidel s Lobe normal anatomic variant; projection of the right lobe that can extend as far as the iliac crest (Tempkin, p.54, Anatomy).
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationAnaesthetic considerations and peri-operative risks in patients with liver disease
Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationGraft Failure From Hepatic Veno-Occlusive Disease After a Liver Transplant: A Case Report
CASe RePORT Graft Failure From Hepatic Veno-Occlusive Disease After a Liver Transplant: A Case Report Tian Shen, Xiaofeng Tang, Hua Xiang, Shusen Zheng Abstract Objectives: Hepatic veno-occlusive disease
More informationNew recommendations for immunocompromised patients
New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption
More informationObservational Medical Outcomes Partnership
Implications of Health Outcomes of Interest Definitions: Acute Liver Injury Case Study Judy Racoosin, Patrick Ryan on behalf of OMOP Research Team Observational Medical Outcomes Partnership Established
More informationThe authors have declared no conflicts of interest.
Diagnostic Accuracy of Magnetic Resonance Cholangiopancreatography Versus Endoscopic Retrograde Cholangiopancreatography Findings in the Postorthotopic Liver Transplant Population Authors: *Ashok Shiani,
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationPORTAL HYPERTENSION. Tianjin Medical University LIU JIAN
PORTAL HYPERTENSION Tianjin Medical University LIU JIAN DEFINITION Portal hypertension is present if portal venous pressure exceeds 10mmHg (1.3kPa). Normal portal venous pressure is 5 10mmHg (0.7 1.3kPa),
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationIndividual Study Table Referring to Part of the Dossier. Use only) Name of Finished Product:
SYNOPSIS Fresenius Title of the study: A double-blind, randomized study comparing the safety and torelance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition Coordinating
More informationTransjugular liver access and biopsy
Transjugular liver access and biopsy An illustrated guide Illustrations by Lisa Clark LABS LIVER ACCESS AND BIOPSY SET MEDICAL Support your procedures by using products that are specifically designed for
More informationAcute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018
Acute Liver Failure Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018 Disclosures None Outline Overview of ALF Management of ALF Diagnosis of ALF Treatments and Support
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdomen, acute, in oncological surgery patients, critical care issues in, 101 102 Acquired factor VIII inhibitors, in critically ill cancer
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More informationDefinitions. You & Your New Transplant ` 38
Definitions Acute Short, relatively severe Analgesic Pain medicine Anemia A low number of red blood cells Anesthetic Medication that dulls sensation in order to reduce pain Acute Tubular Necrosis (ATN)
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationMANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationApproach to the Patient with Liver Disease
Approach to the Patient with Liver Disease Diagnosis of liver disease Careful history taking Physical examination Laboratory tests Radiologic examination and imaging studies Liver biopsy Liver diseases
More informationRisk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis
Original Article Page 1 of 9 Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Rui Sun*, Xingshun Qi* #, Deli Zou, Xiaodong Shao, Hongyu Li, Xiaozhong
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/28461 holds various files of this Leiden University dissertation. Author: Brink, Marloes Hendrika ten Title: Individualized therapeutics in allogeneic stem
More informationImaging Guided Biopsy. Edited & Presented by ; Hussien A.B ALI DINAR. Msc Lecturer,Reporting Sonographer
Imaging Guided Biopsy Edited & Presented by ; Hussien A.B ALI DINAR. Msc Lecturer,Reporting Sonographer Objective By the End of this lessons you should : Define what biopsy Justify Aim to perform biopsy
More informationAlbumin-to-bilirubin score for assessing the in-hospital death in cirrhosis
Original Article Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis Lichun Shao 1 *, Bing Han 1 *, Shu An 2, Jiaxin Ma 1, Xiaozhong Guo 3, Fernando Gomes Romeiro 4, Andrea Mancuso
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationHepatitic variant of graft-versus-host disease after donor lymphocyte infusion
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion Görgün Akpek, John K. Boitnott, Linda A. Lee, Jason P. Hallick,
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationTHAI J GASTROENTEROL 2014 Vol. 15 No May - Aug. 2014
Case Report Poovorawan K, et al. 105 Fatal Acute-on-Chronic Liver Failure from Amiodarone Toxicity Poovorawan K 1,2 Wisedopas N 3 Treeprasertsuk S 1 Komolmit P 1 ABSTRACT Background: Drug induced liver
More informationROUTINE LAB STUDIES. Routine Clinic Lab Studies
ROUTINE LAB STUDIES Routine Clinic Lab Studies With all lab studies, a tacrolimus or cyclosporine level will be obtained. These drug levels are routinely assessed to ensure that there is enough or not
More informationCentral nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients
(2000) 25, 79 83 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome
More informationQuestion No. Clinical Aspect Drop-Down List Response Q1 Primary indication for liver biopsy from original request form Deranged LFTs
Appendix E1 Questionnaire A: Organizational Questionnaire Question No. Question Q1 How many image-guided/assisted liver biopsies in total were performed in your department from 1/1/2008 31/12/2008? Q2
More informationDonor work up, follow up and ethical issues
Donor work up, follow up and ethical issues Hans Hägglund MD. PhD. Associate Professor Hematology Center, Karolinska University Hospital, Stockholm, Sweden Outline The donor has been identified as a match
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationVascular complications in percutaneous biliary interventions: A series of 111 procedures
Vascular complications in percutaneous biliary interventions: A series of 111 procedures Poster No.: C-0744 Congress: ECR 2013 Type: Educational Exhibit Authors: A. BHARADWAZ; AARHUS, Re/DK Keywords: Obstruction
More informationNicole Laferriere MD PhD FRCPC April 10, Patient Case Studies: Sticky Situations For Platelet Transfusions
Nicole Laferriere MD PhD FRCPC April 10, 2019 Patient Case Studies: Sticky Situations For Platelet Transfusions Disclosures Ad Board: Celgene, Jansen, Takeda, Roche, Sanofi, Leo, Shire, Servier, Phizer,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationMr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK
Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK Ms Sally Bufton University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham Mrs Janet Catt Royal Free
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationTata Memorial Centre s opinion is summarized as follows: 1. Given the type 1 stricture (as mentioned in the structured summary), assessment
March 5 th 2016 Dear Ms. Malti Sinha, Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online
More informationINVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests
Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationComplications after HSCT. ICU Fellowship Training Radboudumc
Complications after HSCT ICU Fellowship Training Radboudumc Type of HSCT HSCT Improved outcome due to better HLA matching, conditioning regimens, post transplant supportive care Over one-third have pulmonary
More informationThe Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level
The Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level SIMONA ALEXANDRA IACOB 1, EUGENIA PANAITESCU 2, DIANA
More informationMrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014
Pre-Conference Nurse s Course in partnership with Mrs Janet Catt Royal Free London NHS Foundation Trust Janet Catt MSc RN Lead Nurse Specialist Practic 1 Liver blood tests monitoring cirrhosis HIV/HCV
More informationSafety and utility of percutaneous liver biopsy in hematopoietic stem cell transplant pediatric recipients: a retrospective study
Maximova et al. BMC Cancer (2016) 16:590 DOI 10.1186/s12885-016-2603-8 RESEARCH ARTICLE Open Access Safety and utility of percutaneous liver biopsy in hematopoietic stem cell transplant pediatric recipients:
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationAberrant Expression of Keratin 7 in Hepatocytes as a Predictive Marker of Rapid Progression to Hepatic Failure in Asymptomatic Primary Biliary
2015 69 3 137144 Aberrant Expression of Keratin 7 in Hepatocytes as a Predictive Marker of Rapid Progression to Hepatic Failure in Asymptomatic Primary Biliary Cirrhosis a a,b* a a a a a,b a a a,b c d
More information